Intervention

pembrolizumab (KEYTRUDA®)

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting0

Common conditions13

Lead sponsors shown4

Clinical trials

5 shown

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)NCT06726265 · 2025-03-21

ACTIVE_NOT_RECRUITING

A Study of SEA-CD40 Given With Other Drugs in CancersNCT04993677 · 2021-10-06

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid TumorsNCT04332653 · 2020-06-10

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCCNCT03625323 · 2019-02-21

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With PembrolizumabNCT03674567 · 2018-09-25

Common conditions

Advanced Cancer1 Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)1 Any Advanced Solid Tumors1 Carcinoma, Non-Small- Cell Lung1 HNSCC1 Melanoma1 Microsatellite Stable Colorectal Cancer1 Non Small Cell Lung Cancer1 NSCLC1 Ovarian Cancer1 Pancreatic Cancer1 Small Cell Lung Cancer1 Triple Negative Breast Cancer1

Leading sponsors

Immutep S.A.S.2 NeoImmuneTech1 RAPT Therapeutics, Inc., a member of the GSK plc group of companies1 Seagen Inc.1

Trial status mix

COMPLETED4

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE24

PHASE12

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.